AARD · Aardvark Therapeutics, Inc. Common Stock

The FDA’s full clinical hold on ARD-101 represents a material setback for Aardvark’s lead program and near-term value drivers. The hold directly halts the Phase 3 HERO trial evaluating ARD-101 for hyperphagia in Prader-Willi Syndrome—a high-unmet-need indication—and its companion open-label extension, effectively freezing enrollment, dosing, and primary endpoint assessment. While the filing does not disclose the specific safety or data concerns prompting the hold, it confirms the action followed a prior voluntary pause, suggesting emerging issues were identified during internal review or preliminary FDA feedback. Aardvark’s stated intent to unblind HERO and OLE data signals an urgent effort to assemble a complete safety and efficacy dataset to support regulatory dialogue—yet unblinding may reveal adverse trends that further delay or derail development. The company’s $91.2 million cash position provides runway into mid-2027, but extended delays or additional studies could materially accelerate burn rate. Management’s emphasis on collaboration with the FDA and commitment to the PWS community reflects strategic prioritization of regulatory alignment over speed, though investors face significant uncertainty regarding timing, scope, and likelihood of hold removal. No guidance on potential trial redesign, biomarker requirements, or alternative development paths is provided, leaving the program’s viability highly contingent on forthcoming FDA interactions.